Studying the effect of omega 3 and 6 on the closure of the patent ductus arteriosus in premature infants

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

IRCT

Registry ID

IRCT20231101059922N1

Enrollment

Registered

2025-06-07

Start date

2022-03-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patent ductus arteriosus. Other specified disorders of circulatory system in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Babies under 34 weeks with patent ductus arteriosus who, in addition to the standard treatment with intravenous acetaminophen, receive Omega 3 and 6 drugs at the ra

Eligibility

Sex/Gender

All

Age

1 Days to 28 Days

Inclusion criteria

Inclusion criteria: neonates with a gestational age of less than 34 weeks Age under one month to start treatment Open ductus arteriosus with hemodynamic significance

Exclusion criteria

Exclusion criteria: Neonates with chromosomal abnormalities Toxic neonates Babies with sepsis Babies with congenital heart disease Life-threatening infection Grade 3 and higher intraventricular hemorrhage Right to left shunt Platelet count less than 60 thousand

Design outcomes

Primary

Measure	Time frame
Closed or patent ductus arteriosus. Timepoint: Before the start of the intervention and 3 days after the start of the intervention. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Heidarabadi

Kerman University of Medical Sciences

sheiadarabadi@gmail.com+98 34 3132 8000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026